National Pension Service Grows Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

National Pension Service increased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 345,387 shares of the biotechnology company's stock after acquiring an additional 13,878 shares during the quarter. National Pension Service owned about 0.18% of BioMarin Pharmaceutical worth $24,277,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AGF Management Ltd. acquired a new position in shares of BioMarin Pharmaceutical during the second quarter valued at about $2,563,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of BioMarin Pharmaceutical in the second quarter worth $5,627,000. Teachers Retirement System of The State of Kentucky lifted its stake in shares of BioMarin Pharmaceutical by 17.4% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 194,207 shares of the biotechnology company's stock worth $15,990,000 after buying an additional 28,837 shares during the period. E Fund Management Co. Ltd. increased its position in shares of BioMarin Pharmaceutical by 167.4% in the 2nd quarter. E Fund Management Co. Ltd. now owns 13,480 shares of the biotechnology company's stock valued at $1,110,000 after acquiring an additional 8,438 shares during the period. Finally, Tidal Investments LLC raised its stake in BioMarin Pharmaceutical by 65.5% in the 1st quarter. Tidal Investments LLC now owns 17,447 shares of the biotechnology company's stock worth $1,524,000 after acquiring an additional 6,906 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on BMRN. Bank of America dropped their price target on BioMarin Pharmaceutical from $130.00 to $115.00 and set a "buy" rating on the stock in a research note on Tuesday, September 17th. Scotiabank reduced their price target on shares of BioMarin Pharmaceutical from $95.00 to $78.00 and set a "sector perform" rating for the company in a research report on Tuesday, September 17th. Citigroup dropped their price objective on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a "neutral" rating on the stock in a report on Wednesday, October 30th. Canaccord Genuity Group reduced their target price on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating for the company in a report on Wednesday, October 30th. Finally, Raymond James reaffirmed an "outperform" rating and issued a $79.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, October 10th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.16.

BioMarin Pharmaceutical Price Performance

Shares of BMRN traded up $0.11 during mid-day trading on Friday, hitting $67.05. 683,805 shares of the company were exchanged, compared to its average volume of 1,840,606. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. BioMarin Pharmaceutical Inc. has a 1-year low of $65.35 and a 1-year high of $99.56. The stock has a market cap of $12.78 billion, a price-to-earnings ratio of 40.08, a price-to-earnings-growth ratio of 0.65 and a beta of 0.31. The company has a 50 day moving average of $73.68 and a 200-day moving average of $80.10.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The firm had revenue of $746.00 million during the quarter, compared to analysts' expectations of $703.37 million. During the same quarter last year, the business earned $0.26 EPS. The business's revenue was up 28.4% compared to the same quarter last year. Analysts expect that BioMarin Pharmaceutical Inc. will post 2.47 EPS for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.